Trial Profile

A retrospective study aims to evaluate the efficacy and toxicity of neoadjuvant docetaxel, carboplatin, trastuzumab, & pertuzumab [TCH-P] regimen in early, locally advanced, and oligometastatic (OM) HER2-positive breast cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Docetaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Pegfilgrastim
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
Focus Therapeutic Use

16 Jul 2021 New trial record
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com